Healthcare
Rein Therapeutics Inc.(RNTX)
Live Price
Offline$1.03
-3.74% today
1Y Change
-26.00%
Window
Jun 23, 2025 โ May 29, 2026
- Market Cap
- $30.00M
- Revenue Growth
- 0.0%
- EPS Growth
- +44.2%
- Dividend Yield
- 0.0%
Coverage: 236 bars ยท Jun 23, 2025 โ May 29, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Rein Therapeutics Inc. (RNTX) is a Healthcare stock with a market cap of $30.00M and listed on NASDAQ. The stock last traded around $1.03 and down 26.0% across the available one-year price window (Jun 23, 2025 โ May 29, 2026). Baseline metrics include revenue growth of 0.0%, EPS growth of +44.2%, a dividend yield of 0.0%. What stands out right now is revenue 0.0%, EPS +44.2%, free cash flow +13.1% with operating margin 0.0% and ROIC -120.3%. Stock Foundry combines RNTX price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Sector Context
How this name stacks up against nearby peers on first-pass metrics.
Revenue Growth
Below sector median
0.0% vs +7.6% peer median
Operating Margin
Below sector median
0.0% vs +19.4% peer median
What Changed This Quarter
Latest report context and the signals most likely to have changed the story.
Latest report is on the board
2026 was reported on May 21, 2026, but the surprise data is still limited.
The setup is mixed rather than one-directional
Revenue is 0.0% and EPS is +44.2%, while operating margin sits near 0.0%.
Earnings Reaction Memory
How the stock has tended to move after recent reports.
Across the last 3 reported quarters, the stock averaged +6.8% over the next 5 trading days and finished higher after 2 of those reports.
View quarter-by-quarter reaction table
| Quarter | EPS ฮ | 1D | 5D | 20D |
|---|---|---|---|---|
2026 May 21, 2026 | โ | -1.0% | +6.7% | โ |
2026 Mar 26, 2026 | +0.0% | -1.6% | -4.7% | +30.7% |
2025 Nov 14, 2025 | +12.5% | -2.4% | +18.4% | +18.4% |
Benchmark Comparison
Normalized Performance vs SPY
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
RNTX
โ
Normalized return
SPY
โ
S&P 500
Excess Return
โ
Relative to SPY
RNTX Max Drawdown
-48.43%
Trailing 1Y
SPY Max Drawdown
โ
Trailing 1Y
Calendar-Year Returns
Uses the longest available daily history for RNTX and SPY.
Company Overview
Rein Therapeutics Inc.
NASDAQ Global Market
Rein Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of a novel class of therapeutics for the treatment of cancer and other diseases. It focuses on its lead product candidate, ALRN-6924, which is a cell-permeating peptide that disrupts the interaction of p53 suppressors MDM2 and MDMX with tumor suppressor p53 to reactivate tumor suppression in non-mutant, or wild-type, p53 cancers. The company was founded by Gregory L. Verdine, Rosana Kapeller, Huw M. Nash, Joseph A. Yanchik III, and Loren David Walensky on August 6, 2001 and is headquartered in Austin, TX.
- Leadership
- James Brian Windsor
- IPO Date
- Jun 29, 2017
- Employees
- 11
- Street Address
- 12407 N. Mopac Expy.
- Mailing
- Austin, TX, 78758
- Region
- Austin, TX, US
- Reporting Currency
- USD
- Investor Line
- 737 802 1989
- Last Updated
- May 4, 2026
Key Fundamentals
Valuation, growth, profitability, and balance sheet signals.
Valuation
- P/E
- โ
- EV/EBITDA
- โ
- Price/Sales
- โ
- Price/Book
- 1.5
Growth
- Revenue
- 0.0%
- EPS
- +44.2%
- Free Cash Flow
- +13.1%
Profitability
- Gross Margin
- 0.0%
- Operating Margin
- 0.0%
- Net Margin
- 0.0%
- ROE
- -281.0%
- ROIC
- -120.3%
Balance Sheet
- Debt/Equity
- โ
- Current Ratio
- 0.70
Earnings Reports
Latest News
Official Releases
Company announcements and filings-style updates.
Next Step
Keep the research moving
After the overview, the strongest next step is usually chart context or a tighter compare set.